Compumedics Limited · ASX:CMP
Compumedics — Shareholder Meeting (October 2009)
39 slides from Compumedics's shareholder meeting presentation, October 2009
Slide 1: Annual General Meeting, October 2009
. Innovative ez \ Medical . > Annual General Meeting, October 2009
Slide 2: Agenda
Agenda • Meeting opens • Chairman's address • Ordinary business • Meeting closes
Slide 3: Chairman's address
G COMPUMEDICS “Defining Life's Signals’ Chairman's address ‘Defining Life's Signals’
Slide 4: Compumedics is a world leading supplier of medical technology for patient monitoring
Compumedics is a world leading supplier of medical technology for patient monitoring. Compumedics primary healthcare markets cover sleep, brain and ultrasonic blood flow monitoring. Our Vision is to set the innovative and technological standards for patient monitoring in our chosen markets. We aim t
Slide 5: Global reach
Global reach • Corporate headquarters in Melbourne, Australia • Sales, marketing and support offices in – Melbourne, Australia – Charlotte, N. Carolina, USA – Singen, Germany – Hamburg, Germany • Network of Distributors Globally
Slide 6: Strategic drivers
Strategic drivers • Expanding Compumedics’ key sleep disorder business through new products (Grael™), new diagnostic market opportunities (Home sleep testing – USA and German markets) and sleep-treatment markets with SomniLink® SPAP® • Broadening the scope of Compumedics’ key sleep business through
Slide 7: A brief chronology
A brief chronology • 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. • 1995 the Company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study with 20,000 patient studies completed by 2008. • 1998 awarded the overal
Slide 8: A brief chronology
A brief chronology • In 2004, acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. • 2006, awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product.
Slide 9: Key growth opportunities
Key growth opportunities The current key growth opportunities for the core business continue to evolve from four principal areas being: – The evolution of the home-sleep-testing (HST) market in the US as a result of recent changes to USA private and government funding of HST and the expected growth
Slide 10: Compumedics today: Financials
Compumedics today: Financials 2006 2007 2008 2009 actual actual actual actual Revenues ($m) 37.7 36.7 38.5 38.4 Margins % 52% 58% 58% 57% Other income 1.3 0.1 0.4 0.6 Operating Expenses 22.1 19.5 20.3 19.6 EBITDA (0.5) 1.3 1.9 3.7 NPAT (1.6) 0.1 0.8 2.7 AUD/USD exchange rate 0.73 0.84 0.96 0.75
Slide 11: Compumedics today: Financials
Compumedics today: Financials ≈$40m annual revenues % split by: Business Area Geographic territory Sleep diagnsotics Brain research USA Europe Asia Australia Neuro diagnostics Ultrasonic blood flow Supplies and technical support
Slide 12: Compumedics today: Financials
Compumedics today: Financials • Total revenues resilient at $38.2m compared to $39m in the prior year despite global financial crisis (GFC) • FY2009 record NPAT of $2.7m a 259% increase over the prior year result of $0.8m • Bank debt reduced year-on-year by a further 21% from $2.8m to $2.2m, highest
Slide 13: Compumedics today: Financials
Compumedics today: Financials • Gross margins stable at approximately 57% • Operating expenses less investing activities stable with last year’s spending - $19.7m compared to $19.1m in the prior year • EBITDA up to $3.4m profit compared to prior year profit of $1.9m, a 79% increase over the prior ye
Slide 14: Compumedics today: Financials
Compumedics today: Financials • Borrowings were reduced by a further 21% from $2.8m in the prior year to $2.2m at end of FY2009 • Borrowing costs at $0.6m were 14% lower than the prior year’s $0.7m, a 32% reduction over 2 years • Sales in Asia(21%), Australia(+2%), DWL(+26%) and CSS-USA(135%) were u
Slide 15: Compumedics revenue
Compumedics today: Financials Compumedics revenue AUDm 45.0 40.0 Acqui si ti on of DWL - Ger many 35.0 30.0 Acqui si ti on of 25.0 Neur oscan - USA 20.0 15.0 10.0 5.0 - FY2002 FY2003 FY2004 FY2005 FY2006 FY2007 FY2008 FY2009
Slide 16: EBITDA as reported and without Medical Innovation R&D
Compumedics today: Financials Compumedics - Earnings before interest, tax, depreciation and amortisation (EBITDA) as reported and without Medical Innovation Division R&D spending 5.0 4.0 3.0 AUD million 2.0 1.0 - (1.0) (2.0) (3.0) FY2004 FY2005 FY2006 FY2007 FY2008 FY2009 EBITDA - w/o MI 4.2 (0.6) 1
Slide 17: Debt continues to decline
Compumedics today: Financials Debt continues to decline – a further 21% reduction year-on-year 9 8 7 6 5 AUDm 4 3 2 1 0 2002 2003 2004 2005 2006 2007 2008 2009
Slide 18: Foreign exchange impacts favourably
Compumedics today: Financials Foreign exchange impacts favourably in current financial year 0.8 0.6 0.4 0.2 0 AUDm -0.2 -0.4 -0.6 -0.8 -1 2003 2004 2005 2006 2007 2008 2009
Slide 19: … so how has it turned out so far?
… so how has it turned out so far? • Private company (1999) turnover $9m pa with 45 staff (1 US based) • Listed on ASX (December 2000) – raised $11m (post fees/debt) • April 2002 purchased US based Neuroscan – worlds leading source localisation software – Compumedics turnover $34m, with 120 staff (5
Slide 20: … so how has it turned out so far?
… so how has it turned out so far? • June 2006 Compumedics reduced loss for the year to $1.6m and maintains sales and product development of IP portfolio • June 2008 Compumedics - 2 years into its performance transition program - returned to profits ($0.8m), has grown revenues to $38m despite a risi
Slide 21: Past, present and future
Past, present and future The past, present and future revenue percentage profiles of the business by market/product offering $150m+ SLEEP diagnostic services SLEEP diagnostics Brain research $38m SLEEP diagnostic Neuro Supplies & services diagnostics service SLEEP $9m Brain blood SLEEP diagnostics t
Slide 22: Past, present and future
Past, present and future • The underlying trading performance for the first quarter is similar to last year in terms of sales activities with much stronger sales performances in Germany and the Middle East, Australia continuing to perform solidly and a little change to a very tough American market •
Slide 23: Core products: Sleep – Grael
Core products: Sleep NEW !!! Grael™ World’s first high definition PSG amplifier built on over 20 years of experience – delivering unparalleled signal quality, innovative features and efficiency-enhancing technologies.
Slide 24: Core products: Sleep – Somte
Core products: Sleep Somte PSG The simplest and most convenient way to meet requirements for full PSG … absolutely anywhere. Full PSG ambulatory recorder for attended sleep studies using Blue-tooth wireless technology, or in an unattended ambulatory setting or both. Somté Combined Sleep and CHF moni
Slide 25: Core products: Sleep – Siesta802
Core products: Sleep Siesta802 World leading portable diagnostic device with wireless capability for both sleep and general patient monitoring.
Slide 26: Core products: Sleep – E-Series
Core products: Sleep E-Series Laboratory based diagnostic product for both full polysomnography (PSG) “sleep” studies and or separate EEG studies. First to be “Network-Ready”
Slide 27: Core products: Sleep – ProFusion PSG
Core products: Sleep ProFusion PSG 3 A high-powered comprehensive software companion to our family of leading-edge sleep recorders/ amplifiers. Designed to give sleep medicine professionals everything they need : clarity, power, quality assurance and great reports.
Slide 28: Core products: Brain monitoring – Neuvo LTM
Core products: Brain monitoring Neuvo LTM The state of the art technology platform from Compumedics for Long term EEG monitoring. Bedside display Up to 256 channels Single connection Touch-screen monitor Wall or Mobile configuration
Slide 29: Core products: Brain monitoring – Safiro
Core products: Brain monitoring Safiro Neurodiagnostic excellence in Ambulatory EEG offering convenience, advanced capabilities and confidence in recordings Lightweight and ergonomic 32 Channels Infrared capabilities
Slide 30: Core products: Brain monitoring – Digital Video
Core products: Brain monitoring Digital Video Advanced software and hardware compression technology Synchronised digital video capabilities Accurate image reproduction MPEG4 software compression 32 Bit network performance
Slide 31: Core products: Brain monitoring – ProFusion EEG4
Core products: Brain monitoring ProFusion EEG4 Next generation clinical LTM software package that offers unprecedented ease of use in the EEG lab, and in post-recording analysis and review
Slide 32: Core products: Brain monitoring – Curry
Core products: Brain monitoring Curry 6 Offers extensive possibilities for scientific research investigations in the field of multimodal neuro- imaging. Dipole solutions are obtained using various models and reconstruction methods.
Slide 33: Core products: Brain monitoring – Source and Stim
Core products: Brain monitoring Source Offers impressive source localisation capabilities, including several dipole models and three spheres, BEM and FEM reconstructions. Stim Presents audio and video stimuli and sends stimuli and response to Scan where they are incorporated into the data file.
Slide 34: Core products: Brain monitoring – SynAmps RT
Core products: Brain monitoring SynAmps RT Revolutionary 24-bit acquisition system that offers up to 512 EEG channels with 10G Ohm input impedance and sampling rates capable of up to 20,000 Hertz per channel. The system provides the coordination up of to four headbox units.
Slide 35: Core products: Ultrasonic blood flow
Core products: Ultrasonic blood flow Doppler Box Unique fully digital Doppler M-Mode “Depth of Flow” Display Size and weight of a “pencil box” Modular - Attachable to any PC - “Soft” upgrade to any/all Special Function Tests Embo-Dop Quantum leap in Emboli detection Card based unique clinica
Slide 36: Core products: Ultrasonic blood flow
Core products: Ultrasonic blood flow Multi-Dop Portable Doppler device for complete routine applications, upgradeable for 1- and 2- channel monitoring diagnostics EZ-Dop Compact, portable and modular Doppler for routine diagnostics.
Slide 37: Summary
Summary • World class patient monitoring Company • Uniquely placed in key global markets with strong growth opportunities • Performance transition program continues with solid outcomes delivered, profits and cash growing - balance sheet strong – net cash position • Established routes to market in ke
Slide 38: Ordinary business
Ordinary business • Item 1 Financial Statements and Reports (non binding resolution) • Item 2 Election of a Director • Item 3 Adoption of Remuneration Report (non binding resolution) • Item 4 Approval of RCNs
Slide 39: . Imnovative ek
. Imnovative ek “ Medical ¥